Please login to the form below

Not currently logged in

Banner Banner Alzheimer's Institute

This page shows the latest Banner Banner Alzheimer's Institute news and features for those working in and with pharma, biotech and healthcare.

Lilly and Banner Alzheimers Institute collaborate on donanemab prevention trial

Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial

Eli Lilly and Banner Alzheimer’s Institute have signed a strategic research collaboration to conduct a phase 3 prevention trial of donanemab. ... The Banner Institute will leverage its expertise in Alzheimer’s prevention trials and also support

Latest news

  • Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms Amgen and Novartis abandon Alzheimers drug after worsening symptoms

    Latest BACE inhibitor to run into trouble. Amgen, Novartis and Banner Alzheimer's Institute are to halt trials of their BACE1 inhibitor CNP520 (umibecestat) after some participants taking the drug saw ... Nevertheless David Reese says: "We still believe

  • Mixed findings for Roche in Alzheimer's study Mixed findings for Roche in Alzheimer's study

    successful than those conducted on people who already are experiencing dementia symptoms," said the US-based Alzheimer's Association in a statement. ... Crenezumab is already being tested in an AD prevention study called API-ADAT, led by the Banner

  • Novartis launches Alzheimer’s prevention study Novartis launches Alzheimers prevention study

    The pharma company will work with Banner Alzheimer's Institute (BAI) on a study involving 1, 300 adults aged 60 to 75 who do not have the disease but have been ... David Epstein, division head at Novartis Pharmaceuticals, said the trial plans took

  • US NIH provides $45m for Alzheimer’s research US NIH provides $45m for Alzheimers research

    science advances in Alzheimer's research had not yet resulted in effective treatments or preventative measures. ... The research project to receive the bulk of the fund is a five-year prevention trial led by Dr Eric Reiman and Dr Pierre Tariot of Banner

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    Alzheimer's disease (AD) is the most common type of dementia and in Europe it accounts for 61 per cent of all dementia cases. ... The first trial (organised by the Banner Alzheimer's Institute in the US) will assess crenezumab and a BACE inhibitor in

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    Earlier this year, Amgen, Novartis and Banner Alzheimer’s Institute abandoned a research trial of an Alzheimer’s candidate after some participants taking the drug deteriorated faster than those on the ... A new company has been created from

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...